Literature DB >> 7909672

Surgical treatment of left ventricular aneurysm--assessment of risk factors for early and late mortality.

E Ståhle1, R Bergström, S O Nyström, B Edlund, I Sjörgren, L Holmberg.   

Abstract

Consecutive patients operated on for left ventricular aneurysm from 1970 through August 1989 (n = 303) were evaluated with respect to survival. Early mortality, i.e. within 30 days, was 8.9%; 23% in patients who underwent aneurysm resection alone, 8.1% in cases of aneurysm resection with coronary artery bypass grafting (CABG), and 6.3% in those undergoing CABG only. Multivariate logistic regression revealed that advanced New York Heart Association (NYHA) functional class, non-use of the internal mammary artery as a graft and thromboendarterectomy increased the early risk. The total observed survival was 86% at 1 year, 72% at 5 years and 45% at 10 years. Multivariate analysis based on observed survival, using the Cox proportional hazards model, identified advanced NYHA functional class and non-use of the internal mammary artery as independent indicators of poor survival. Relative mortality, defined as the ratio of observed mortality in the study group to mortality among comparable persons from the general Swedish population, was used as a measure of disease-specific mortality. An apparent excess mortality in patients operated on for left ventricular aneurysm was found. A notable finding was that the use of the internal mammary artery to graft the left anterior descending artery improved the outcome substantially in patients with a left ventricular aneurysm.

Entities:  

Mesh:

Year:  1994        PMID: 7909672     DOI: 10.1016/1010-7940(94)90094-9

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  1 in total

1.  Left ventricular aneurysmal repair within 30 days after acute myocardial infarction: early and mid-term outcomes.

Authors:  Bektas Battaloglu; Nevzat Erdil; Vedat Nisanoglu
Journal:  Tex Heart Inst J       Date:  2007
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.